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SUMMARY. Necrotizing enterocolitis (NEC) of infants is a devastating disease that is both diffi cult to treat and to effec-
tively predict its development. Its occurrence and progression are associated with a plethora of possible causes. That is 
why, in recent years, many studies were made with the intent of fi nding effi cient new ways of treatment and prevention. 
Some of those were designed to study and isolate specifi c factors found in maternal milk and others were more focused 
on testing synthetic molecules or natural remedies. The etiology of NEC and its epidemiology, followed by a character-
ization of the pathology and pathogenesis, as well as symptomatology, clinical, radiological, and biochemical methods 
of detection.
New possible treatment methods and techniques are briefl y described: insulin-like growth factor, human milk oligosac-
charides, epidermal growth factor family, transforming growth factor β, an enzyme – alkaline phosphatase, vitamin A, 
trefoil factor family, branch chain fatty acids, erythropoietin, oxygen, and ozone. Particular emphasis is given to the role 
of maternal milk as a source of many of biochemical factors in prevention and even treatment of NEC. Further investiga-
tions are needed to decrease the incidence and severity as well as to improve the chances of NEC patients.
Introduction to NEC
Necrotizing enterocolitis is an acute infl ammatory in-
testinal disease that affl icts infants and causes necrosis 
of the intestinal wall and may lead to perforation, sep-
sis, systemic organ failure. It is one of the leading causes 
of mortality and morbidity in premature infants.
Etiology is yet unclear with many factors being associ-
ated with NEC development. The most prominent ones 
are prematurity and low birth weight in relation to it, 
childbirth complications, and excessive enteral feeding. 
Among others, we can fi nd respiratory illnesses, heart 
malformations, gut microbiome changes, caesarian sec-
tion delivery, maternal diabetes, excessive antibiotic us-
age, chorioamnionitis, preeclampsia, prenatal exposure 
to indomethacin and the use of said medication for ductus 
arteriosus (Botalli) closure and many more.
As much as 90% of NEC patients are premature ba-
bies. The risk grows with shorter pregnancy and lower 
birthweight with 12% of very low birth weight (VLBW) 
infants becoming ill and roughly 30% of patients suc-
cumb to the disease. It is also a major driver of health-
care costs with up to 19% infant care funds being used 
for its treatment.
Necrotizing enterocolitis primarily affects the large 
intestine, but it may also affect the small intestine or a 
combination of both. It mostly causes skip lesion rather 
than damaging the bowels in continuity. It can result in 
lesions of various thickness – ranging from epithelial 
damage to perforation. NEC is accompanied by intesti-
nal edema, intraluminal bleeding, and interstitial pneu-
matosis – accumulation of gas bubbles in the intestinal 
wall. Many patients with full thickness lesions develop 
adhesion which can inhibit normal intestinal function 
and can lead to further complications.
Pathogenesis is complicated by many elements com-
ing into play at the same time and exacerbating each 
other. The main factors are ischemia, which is suspected 
to be caused by an underdeveloped intestinal blood sup-
ply or an autonomous nervous system dysfunction, and 
pathological bacterial colonization. An increased sus-
ceptibility to bacterial damage might be the result of the 
underdeveloped intestinal selective barrier. In combina-
tion, these factors cause lesions that increase permeabil-
ity and in term promote a more suitable environment for 
bacteria to thrive and that leads to worsening of isch-
emia.
The illness presents itself with a plethora of symp-
toms ranging from feeding intolerance, stagnation in 
weight gain or even in fact a weight loss, vomiting, fe-
ver, distended abdomen and bloody diarrhea. Later on 
as dehydration sets in the infant becomes hypotonic, 
tachycardic, exhibits abnormal breathing patterns as a 
result of acidosis, and fi nally loses consciousness.
It is diagnosed through a combination of clinical 
methods, i.e. paying special attention to prematurely 
born children and having an expectative attitude to-
wards possible symptoms arising, radiological methods 
and blood tests. Signifi cant X-ray signs of NEC are dis-
tended intestines and air-fl uid levels that indicate ileus, 
and the presence of gas bubbles in the intestinal wall. 
Later perforation may lead to an accumulation of air un-
der the diaphragm that is best visible in an upright 
stance. Another important part of diagnosing is com-
plete and differential bloodwork, biochemical and mi-
crobiological tests. A decrease in red blood cells indi-
cates bleeding. Increase in neutrophil levels in correla-
tion with increased CRP and SE levels indicates the 
presence of infl ammation and infection and a severe 
decrease in neutrophil numbers is also associated with a 
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worsened outcome. Thrombocyte levels in relation to 
coagulation parameters indicate susceptibility to bleed-
ing. Acid-base status and ion concentrations are an im-
portant measure of hydration. Microbiological tests are 
necessary as NEC is often associated with bacteremia 
and sepsis. The severity of NEC is determined by Bell’s 
criteria.
The treatment is proportional to disease severity and 
it includes non-surgical and surgical methods – in the 
most severe cases. Traditionally, conservative treatment 
is limited to supportive therapy which includes a cease 
in enteral food intake and intestinal decompression 
which is achieved through a nasogastric probe. Suffi -
cient nutrient intake is accomplished by parenteral feed-
ing in which a central venous line is inserted in the up-
per hollow vein through the subclavian vein. Dehydra-
tion and blood pH levels are corrected by administering 
saline and sodium bicarbonate solution. Application of 
various blood derivatives might be necessary to miti-
gate the loss of blood or specifi c coagulation factors, 
but they also might increase the likelihood of negative 
health outcomes. Antibiotics are administered to pre-
vent the development of infections and to treat them 
when they do occur, but they also damage the natural, 
protective intestinal fl ora which in turn makes the intes-
tines more vulnerable. Finally, in severe cases it might 
be unavoidable to perform a surgical procedure to re-
move the devitalized tissue. Needless to say, an opera-
tion is hard to bare for infants and it carries with it the 
risk of long lasting complications for digestion. This 
paper examines novel methods that would directly in-
crease the fortitude of the intestinal wall and also in-
crease its ability to recuperate so as to avoid the more 
aggressive forms of treatment that we have at our dis-
posal today. These new treatment options could also 
have a positive effect on weight gain and overall well-
being.
New treatment methods for NEC of infants
Insulin-like growth factor 1 (IGF1)
Insulin-like growth factor 1 is a peptide hormone 
made up of four domains A, B, C, and D. It is mainly 
produced in the liver, but IGF 1 can be found in cells 
throughout the body including osteoblasts, skeletal 
muscle cells, renal cells, etc. The main stimulus for its 
production comes from human growth hormone, al-
though insulin, nutritional status, and other factors in-
fl uence its production. It is one of the main anabolic 
hormones in the body. It can also be found in human 
milk and a positive correlation between high concentra-
tions of IGF 1 and faster velocity of infant growth has 
been observed (1). On the other hand, low serum levels 
of IGF 1 in premature infants play a role in a multitude 
of illnesses such as NEC, bronchopulmonary dysplasia, 
intraventricular hemorrhage, and they can stifl e retinal 
and cerebral development (2). It was demonstrated in 
animal studies that intraperitoneal injections of IGF 1 
can reduce intestinal apoptosis and necrosis as a result 
of hypoxia (3) and that enteral intake can reduce infl am-
mation, incidence of NEC and its severity (4).
Human milk oligosaccharides (HMOs)
Human milk oligosaccharides are a group of roughly 
200 oligosaccharides made up of two dozen different 
monosaccharides. The number of them in breastmilk 
varies from mother to mother, ranging from 23 to 130. 
Most of them are utilized as prebiotics for the intestinal 
fl ora as they are not digestible by infants. It was deter-
mined that a mixture of short chain galacto-oligosac-
charides/long-chain fructo-oligosaccharides signifi -
cantly reduces the incidence of NEC (5). In an attempt 
to single out specifi c oligosaccharides responsible ad-
ditional in vitro studies were undertaken. They have 
shown that certain HMOs, namely 3’-sialyl-lactose and 
3’-sialyl-3-fucosyl-lactose can reduce adhesion of leu-
kocytes to endothelial cells which may provide anti-in-
fl ammatory properties (6). Furthermore, it was demon-
strated that a specifi c oligosaccharide – disialyllacto-N-
tetraose (DSNT) can reduce NEC incidence both in rats 
and humans (7), and that DSNT might also be used as a 
non-invasive marker for NEC prone infants (8). It was 
also shown, in an animal model, that 2’-fucosyllactose 
has a protective effect, although not as pronounced as 
DSNT, while galacto-oligosaccharides provide no ap-
parent benefi t (9).
Some studies show opposite effects, with one study 
demonstrating that a combination of short-chain galac-
to-oligosaccharides/long-chain fructo-oligosaccharides 
and acidic oligosaccharides does not reduce intestinal 
permeability (10). In addition to that, a very recent ani-
mal study has shown that even though HMOs reduce 
infl ammation they do not change NEC incidence and 
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may, in fact, increase the likelihood of dehydration and 
diarrhea (11).
Epidermal growth factor family
EGF-family is a group of peptide growth factors con-
sisting of epidermal growth factor (EGF), heparin-bind-
ing EGF-like growth factor (HB-EGF), transforming 
growth factor-α (TGFα), amphiregulin, betacellulin, 
epiregulin, epigen and the four neuregulins. They all 
share a similar structure and function and function as 
ligands for the epidermal growth factor receptor family. 
EGFR family consists of four members: ErbB1 (HER1), 
ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). 
From a perspective of pediatrics, the two most well 
studied and interesting factors in that group are EGF 
and HB-EGF. Both of them can be found in human 
milk, with EGF being present at 2 to 3 times higher con-
centrations. It was also determined that the concentra-
tion of EGF does not change with regard to the length of 
the pregnancy. On the other hand, it was shown that lev-
els of salivary EGF vary with gestational age, being 
lower in prematurely born infants, and that lesser con-
centrations strongly correlate to the risk of NEC devel-
opment (12). Furthermore, animal studies have demon-
strated that enteral application of EGF reduces both the 
risk of NEC development and its severity (13). Those 
effects might be explained, in part, by the fact that EGF 
was demonstrated in an animal model to reduce the lev-
els of proinfl ammatory cytokines, mainly IL 18, and 
increases anti-infl ammatory ones like IL 10 (14). Other 
animal studies have pointed out its antiapoptotic effect 
that is achieved through reducing the activity of kas-
pase-3 and Bax proteins and increasing Bcl-2 expres-
sion (15). In addition to that, it was also discovered, on 
a rat model, that EGF protects the integrity of the intes-
tinal barrier through decreasing intestinal paracellular 
permeability, normalizing expression of two major tight 
junction proteins, occludin and claudin-3, and increas-
ing goblet cell density and mucin production, in the il-
eum (16).
HB-EGF was proven through numerous genetic stud-
ies to be an effective tool in fi ghting against NEC. One 
study with HB-EGF ((–/–)) knockout (KO) mice dem-
onstrated a higher susceptibility to NEC development 
that was mitigated with enteral HB-EGF supplementa-
tion (17). Another study used an opposite approach in 
which transgenic mice with an overexpressed HB-EGF 
were exposed to an experimental NEC model. They 
showed a drastic decrease in NEC incidence and intes-
tinal permeability (18). HB-EGF achieves its effect 
through several pathways. One of them seems to be that 
it signifi cantly increases intestinal microvascular blood 
fl ow. Another way is its cytoprotective effect on intesti-
nal cells exposed to hypoxia, and the ability to expedite 
proliferation and recovery. HB-EGF was also proven to 
reduce the expression of adhesion molecules such as 
platelet and endothelial selectins and of intercellular ad-
hesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule (VCAM-1). It also, in animal models, reduces 
polymorphonuclear cell infi ltration (19). Furthermore, 
HB-EGF decreases reactive oxygen species (ROS) pro-
duction in intestinal cells exposed to stress, and it also 
reduces apoptosis as a result of infl ammation on in vitro 
models (20).
Transforming growth factor β 
(TGF-β)
Transforming growth factor β is divided into three 
different subgroups of signaling peptides: TGF-β sensu 
stricto, bone morphogenic proteins and activins. TGF-β 
has four structurally very similar sub variants that play 
a role in numerous cellular interactions. TGF-β2 seems 
to be to most prominent member of the group when it 
comes to potential benefi cial effects on intestinal health. 
It was shown in animal studies that lesser TGF-β2 ex-
pression positively corelates with NEC development 
(21). In addition to that TGF-β2 also has anti-infl amma-
tory and anti-stress properties on intestinal cells as a 
result of changing the expression of up to 20 different 
proteins. It was also demonstrated on mice and in in vi-
tro conditions that TGF-β2 reduces the activity of intes-
tinal macrophages and promotes their noninfl ammatory 
differentiation during gestation. That is one of the many 
reasons why premature infants have a higher risk of de-
veloping NEC due to their shorter development process 
(22). TGF-β is also present in human milk and it was 
shown that it had lower bioactivity in mothers who had 
shorter gestation. It was also determined that latent 
TGF-β can be activated through the use of enzymatic 
activation with neuraminidase (23). An additional study 
was undertaken to examine the effect of adding recom-
binated TGF-β2 to human milk. It failed to increase its 
bioactivity as a result of TGF-β2 being bound to chon-
droitin sulfate. Enzymatic treatment with chondroitin-
ase increased the activity of both the endogenous and 
exogenous TGF-β2 (24). Further human trials for TGF 
and its activation methods are necessary.
Alkaline phosphatase
Alkaline phosphatase is a homodimeric protein found 
in many organisms. It is an enzyme that catalyzes the 
reaction of dephosphorylation in alkaline environments. 
Humans have four iterations of this protein: intestinal 
(IAP), placental, tissue-nonspecifi c (liver-bone-kidney 
type) and germ cell. They are named after tissue in 
which they are most prevalent, but can also be found 
throughout the body. The most interesting one is the in-
testinal variant. Enteral supplementation with IAP was 
shown to reduce the expression of pro-infl ammatory 
cytokines in the intestines and decrease nitrosative 
stress in animal models (25). It was also shown, on ani-
mal models, that enteral supplementation reduces the 
systemic levels of IL-1β, IL-6, and TNF-α in a dose de-
pendent manner (26). Additional studies demonstrated 
that IAP activity is lowered in the gut affl icted with 
NEC and that addition of IAP to the diet reduces intes-
tinal injury severity and may improve the integrity of 
the intestinal barrier (27).
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Vitamin A
Vitamin a is a generic term that encompasses a pleth-
ora of compounds. Retinol and retinyl esters are called 
preformed vitamin A, and β-Carotene and other carot-
enoids are called previtamin A and can be converted into 
retinol in the body. Retinol can then be turned into reti-
nal, and it into retinoic acid. Vitamin A compounds are 
fat soluble and stored in the liver. They take part in nu-
merous processes and regulate gene expression. It was 
demonstrated that very-low-birth-weight infants pre-
dominantly have a decreased concentration of vitamin A 
in the plasma and that it correlates to impaired develop-
ment (28). It was also demonstrated in animal studies 
that intraperitoneal application oh high doses of vitamin 
A can improve intestinal healing after injury, reduce co-
lon wet weight, which is a sign of edema, and hasten 
weight gain (29). Further studies examined the specifi c 
molecular pathway through which vitamin A achieves its 
effect. It was demonstrated in vitro that all-trans-retinoic 
acid can increase the expression of TGF-β2, whose role 
was already discussed in this text (30). Furthermore, as 
demonstrated on rats, another way might be by decreas-
ing the expression of TNF-α and increasing the activity 
of antioxidative enzymes like superoxide dismutase and 
glutathione peroxidase (31).
Trefoil factor family (TFF)
Trefoil factor family is a group consisting of three 
small peptides expressed by mucus-producing cells in a 
variety of tissues. They are most prevalent in the intes-
tinal tract. TFF 1 (also known as sP2), TFF 2(also 
known as SP), and TFF 3 (also known as TFI) are abun-
dantly present in the stomach, colon, and ductus of pan-
creas, whereas TFF 1 and 3 can also be found in other 
parts of the gastrointestinal tract. All of them are present 
in human milk, with TFF 3 being detectable in the high-
est concentrations. All of their levels drop signifi cantly 
during the fi rst few weeks after pregnancy. It was also 
determined that their enteral application drastically im-
proves the colitis score, with TFF 3 dimer being the 
most effective. On the other hand, subcutaneous injec-
tions were shown to aggravate the infl ammation in rats 
(32). TFF 3 was also demonstrated to be not only effec-
tive for treatment but also prevention. One of the rea-
sons for their protective properties seems to be that they 
interact with mucins to create a more viscous, elastic 
mucus. TFF 2 was proven to the most potent in doing 
that. Furthermore, TFF3 was shown to have strong anti-
infl ammatory properties with its effect on reducing IL 8, 
TNF-α, prostaglandin E2, thromboxane B2, nitric oxide 
and malondialdehyde expression in intestinal tissue.
Branch chain fatty acids (BCFAs)
Branch chain fatty acids are mostly saturated, meth-
ylated fatty acids. They are categorized as mono-, di-, or 
multi-methyl BCFA with regard to the number of meth-
yl groups. They are rare in internal organs but can be 
found in the skin, and they are a core component of ver-
nix caseosa, a creamy white substance covering the 
newborns, making up 10–29% of its composition. Fur-
thermore they can also be found in human milk. BCFAs 
have been shown to reduce infl ammation in intestinal 
cells in vitro and more recent studies demonstrated that 
oral supplementation can increase the production of IL 
10 – a pleiotropic immunoregulating peptide with a 
multitude of effects that include the downregulation of 
pro-infl ammatory cytokines and co-stimulatory mole-
cules, and a reduced expression of HLA2 antigens. In 
addition to that, it was demonstrated on rats, that they 
promote the development of a healthier gut fl ora and 
reduce NEC incidence by 50% (33).
Erythropoietin (EPO)
Erythropoietin, sometimes also called hematopoietin, 
is a glycopeptide hormone produced mostly by peritu-
bular fi broblasts in the renal cortex. He is also produced 
in the brain, liver, spleen, lung and testis, but in minute 
quantities. Prenataly EPO is mainly produced by hepa-
tocytes. The main stimulus for its production is hypox-
ia. In turn, he acts as an anti-apoptotyc agent for the 
erythrocytic lineage, mainly the colony-forming units-
erythroid (CFU-Es) in the bone marrow and other he-
matopoietic organs. Although elevated blood levels of 
EPO in preterm infants were shown to correlate with 
NEC development (34), possibly because high levels 
are a sign of severe anemia, recent studies have shown 
the benefi cial effect of EPO on enterocytes. EPO is a 
component of human breastmilk and was proven to re-
duce cell necrosis in vitro, possibly through increasing 
glutathione levels (35). It also reduces autophagy and 
apoptosis both in vitro and in vivo, on rats, in intestinal 
cells via the different signaling pathways (36).
Oxygen and ozone
Hyperbaric oxygen (HO) has been used in a variety 
of conditions ranging from necrotizing fasciitis to de-
compression sickness. It is proven to promote expres-
sion of antioxidative enzymes and enhance angiogene-
sis. A study has demonstrated that an application of HO 
can reduce infl ammation markers and injury scores in a 
NEC model. Furthermore, a human pilot study has 
demonstrated that a brief application of HO has no ad-
verse effects and might be used for NEC treatment (37). 
Ozone (O3) is a triatomic allotrope of oxygen. He is 
often associated with detrimental effects on human 
health. When inhaled, it was shown to irritate the respi-
ratory tract mucosa, exacerbate asthma and bronchitis, 
increase the likelihood of heart attacks, and may even 
lead to premature death. For all of those reasons it is 
understandable that there is skepticism towards ozone 
and its application in medicine. Nevertheless, recent 
studies have demonstrated that rectal and intraperito-
neal application of ozone has the ability to reduce the 
levels of infl ammation markers in the intestines. In ad-
dition to that, intraperitoneal administration can also 
reduce oxidative stress and mortality, and ameliorate 
weight loss in rats (38). It was also demonstrated, on 
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animal models, that when compared, ozone has a better 
overall effect on NEC than HO (39).
Proper enteral feeding
Given the fact that a signifi cant number of com-
pounds mentioned in this article are contained in mater-
nal milk and that for the foreseeable future maternal 
milk will stay as the primary source of these molecules, 
at least until they are verifi ed in their effectiveness and 
until we are able to produce them in larger quantities, it 
is appropriate to give a review of various combinations 
of enteral feeding methods. They include maternal milk, 
fortifi ed maternal milk, formula, and combinations of 
the aforementioned. It is also important to note that 
when it comes to prematurely born infants there are 
great variations in gestational age and birth weight and 
as a result of that – great variations in gastrointestinal 
tract development. That naturally leads to different en-
teral nutrient intake capacity and risk of feeding intoler-
ance and other complications, such as NEC. It is very 
hard to draw the line between different age and weight 
classes of infants and assign a specifi c feeding regimen 
to them. That is why the common wisdom about the 
diets of VLBW and extremely low birth weight (ELBW) 
infants changes throughout the years and is a topic of 
fi erce debate. There is a general consensus of scientifi c 
evidence that shows that maternal milk diet is highly 
preferable to formula feeding. Not only that, it was also 
shown that exclusive human milk diet outperforms ma-
ternal milk with bovine fortifi er, and a combination of 
fortifi ed milk and formula. The reduction in NEC inci-
dence is signifi cant with other benefi ts such as: reduced 
feeding intolerance, days to full enteral feeding, and 
shorter hospital stay. In a situation when maternal milk 
is not available we are left with the choice of donated 
milk or formula. Studies have shown that formula based 
nutrition, in the short run, leads to faster weight gain, 
and an increased head circumference and body length. 
In the long run those infants did not retain their growth 
advantage nor did they have superior neurodevelop-
mental outcomes. On the other hand, infants that were 
fed with donated milk had a lower incidence of NEC 
(40). Given the fact that the majority of children, in a 
case that they do not have access to maternal milk, will 
also not have access to donated milk, doctors must ap-
ply formula in a proper manner. Studies have demon-
strated that while maintaining a suffi cient calorie intake 
of 110–130 kcal/kg/day, and a protein intake of 3–4 g/
kg/day for VLBW infants and 4–4.5 G/kg/day for 
ELBW infants (41) is necessary, it might be wo rth con-
sidering lowering the concentration of the formula so as 
to reduce the risk of feeding intolerance. Further studies 
are necessary.
Two other important aspects of enteral nutrition that 
must be considered are the proper time after birth to 
introduce enteral nutrition, and a proper volume of food 
that ought to be applied. It is a general attitude that par-
enteral nutrition should be reduced given the fact that it 
carries a risk of malnutrition and serious metabolic dis-
balances. Majority of the studies agree that minimal en-
teral nutrition should be started within the fi rst four days 
for VLBW infants with the intent of stimulating muco-
sal function, intestinal motility and preventing atrophy. 
Beyond that point there is a divergence in fi ndings and 
attitudes towards the increase in volume of intake. Cer-
tain studies propose that for the fi rst ten days the vol-
ume should not be greater than 24 mL/kg/day and that 
this regimen has a positive effect on the reduction of 
feeding intolerance, and the risk of NEC and its severity 
(42). On the other hand there are studies that propose a 
more aggressive approach which includes increasing 
the feeding volume by 20–30 mL/kg/day for VLBW 
and 15–25 mL/kg/day for ELBW infants. Their reason-
ing is that it will reduce the chance of insuffi cient calo-
rie intake, increase growth, reduce the time necessary to 
achieve full enteral feeding, and that it does not increase 
the risk of NEC (41). Finally, there is evidence that for 
ELBW infants under 750g it might be benefi cial, in 
terms of NEC avoidance, to have a regimen that com-
pletely excludes enteral nutrition for up to two weeks 
and then slowly introduces it through a period of sev-
eral weeks (43).
Discussion
NEC is still one of the main problems of infant health 
care and there haven’t been many drastic changes in pa-
tient health outcome in the last decade. It has a rela-
tively high mortality and morbidity and it is a problem 
that is not going to go away anytime soon due to the fact 
that the capacity of modern medicine to sustain life in 
extremely premature infants is ever expanding. That is 
why this article focuses on new methods of treating 
NEC that may provide a much-needed breakthrough. 
As far as treatment is concerned there is a multitude of 
compounds that have a possibility of being used one 
day on their own, or in combination, for prevention, 
treatment, and reduction of NEC severity and mitigat-
ing its infl uence on the body. They can be molecules 
found in human milk like insulin-like growth factor 1, 
human milk oligosaccharides, epidermal growth factor 
family, transforming growth factor β, erythropoietin. 
Others are a part of human milk and are also produced 
by the infant, such as branch chain fatty acids and trefoil 
factor family. There is also alkaline phosphatase, vita-
min A, ozone and oxygen – a gas already present in the 
treatment of respiratory illnesses that affl ict newborns.
Finally, the best NEC prevention tool is maternal 
milk. The most diffi cult thing is to resolve the puzzle of 
its administration in terms of volume and the proper 
time frame in which it ought to be applied. A certain 
level of consensus exists but further studies are required 
to fully optimize the clinical use.
This paper focused to highlight relevant human and 
animal studies, as to bring them to the attention of the 
medical community. It must be emphasized that all of 
these clinical tools are still in their experimental and 
developmental stage and that they require much further 
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study, but that they also provide a wide arrange of op-
portunity that ought to be explored.
In conclusion, it must be noted that the best treatment 
is prevention and early detection. Additional studies 
must also focus on a wide range of molecules, currently 
being investigated, that have a possibility of one day 
giving us an insight in the early stages of NEC develop-
ment so as to facilitate a quick and appropriate response.
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NEKROTIZIRAJUĆI ENTEROKOLITIS DOJENČADI 
– NOVE MOGUĆNOSTI LIJEČENJA
Mislav Knežević1, Josip Juras2, Jurica Vuković3, Boris Filipović-Grčić3
Stručni članak
Ključne riječi: nekrotizirajući enterokolitis, dojenčad, nove mogućnosti liječenja
SAŽETAK. Nekrotizni enterokolitis (NEC) dojenčadi razorna je bolest koja zahtijeva intenzivno liječenje te čiji je razvoj 
teško predvidjeti. Njegova pojava i progresija povezani su s mnoštvom mogućih uzroka. Zato su posljednjih godina 
mnoge studije napravljene s namjerom pronalaženja učinkovitih novih načina liječenja i prevencije. Neki od njih su 
 dizajnirani za proučavanje i izoliranje specifi čnih čimbenika pronađenih u majčinom mlijeku, a drugi su bili više 
usredotočeni na ispitivanje sintetičkih molekula ili prirodnih lijekova. Etiologija NEC-a i njezine epidemiologije, nakon 
čega slijedi karakterizacija patologije i patogeneze, kao i simptomatologije, kliničke, radiološke i biokemijske metode 
detekcije.
Kratko su opisane nove metode i tehnike liječenja: faktor rasta sličan inzulinu, oligosaharidi ljudskog mlijeka, obitelj 
epidermalnog faktora rasta, transformirajući faktor rasta, enzim-alkalna fosfataza, vitamin A, obitelj trefoil faktora, 
masne kiseline lanca grana, eritropoetin, kisika i ozona. Poseban naglasak stavljen je na ulogu majčinskog mlijeka kao 
izvora mnogih biokemijskih čimbenika u sprječavanju i čak liječenju NEC-a. Potrebne su daljnje istrage kako bi se 
smanjio učestalost i ozbiljnost, kao i poboljšali šanse za pacijente s NEC-om.
